Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Court Ruling Compels Emergency Contraceptives Over The Counter

This article was originally published in The Tan Sheet

Executive Summary

Under a federal judge’s order, FDA must reverse its denial of the Center for Reproductive Rights’ 12-year-old citizen petition and allow universal OTC access to Plan B One-Step and equivalent levonorgestrel-based emergency contraceptives within 30 days.

You may also be interested in...



Like Plan B, Approval For OTC Daily Oral Contraceptives In US Could Be An 'Adventure’

It was only after prolonged litigation led a federal judge in 2013 to order FDA not to allow political interference with its science-based decisions that Plan B and generic equivalents became available OTC without age restrictions. “Hopefully, all I can say, it won't happen again,” says reproductive rights advocate Kirsten Moore.

Pandemic Makes OTC Access To Daily Oral Contraceptives More Critical, Experts Tell FDA

Nearly 120 researchers, clinicians and advocacy groups have signed a letter to be sent in late August urging FDA to prioritize completion of a review process to make oral contraceptives available OTC.

Sun Pharma US Business Co-packages OTC Emergency Contraceptive With Pregnancy Test

My After Plan has been available online and in stores since October 2020, shortly before Sun Pharma received registration for the trademark in the US. Recently, marketing and design consultants announced their work for Sun Pharma's Ohm Labs on My After Plan packaging.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel